ClinicalTrials.gg
TerminatedNCT06851442Updated Dec 12, 2025

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

A Phase 1/2 interventional study of TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules in Breast Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Terminated at 17 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited — 11 open to participants now, 16 under way, 8 of them phase 3. Breast Neoplasms · Sino Biopharmaceutical Limited.

Enrollment
27th of 28
8 · median 138
Started
2025
with 6 others
Phase 1/2
5 of 28
2 open now
Registered
21st of 28
by date

Among the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, this one is the 27th largest by enrollment, is one of 7 that started in 2025, is one of 5 in phase 1/2, and was the 21st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This trial was designed to evaluate the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) in subjects with TQB3912 tablets combined with fulvestrant injection and TQB3616 capsules for locally advanced or metastatic HR-positive and HER2-negative breast cancer.And the effectiveness of TQB3912 tablets combined with fulvestrant injection ±TQB3616 capsules in locally advanced or metastatic HR-positive and HER2-negative breast cancer subjects was evaluated by evaluating ORR, PFS, DOR, DCR, CBR, OS, etc., and at the same time, Assess its safety and pharmacokinetic (PK) characteristics.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects voluntarily joined the study, signed an form, and had good compliance.
  • Age: 18-75 years old; (ECOG) Performance Status (PS) score: 0\~1 point; estimated survival time exceeds 3 months.
  • Women can be in the late period of menopause and before menopause/innerspring. If they are before menopause/siege period, they must continue to receive ovarian function inhibitory treatment during the research period to enter the group.
  • Anthropologically confirmed HR-positive and -negative breast cancer.
  • Locally advanced or diseases that cannot undergo radical surgery.
  • Queue 1 Previous treatment requirements: progress after endocrine therapy; Queue 2 Previous treatment requirements: progress after endocrine therapy.
  • Have one or more phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)/v-akt murine thymoma viral oncogene homolog 1 (AKT1)/phosphatase and tensin homolog deleted on chromosome ten (PTEN) gene mutations.
  • At least one exists according to the 1.1 standard.
  • Good function of the main organs
  • Female subjects of childbearing age should agree that measures (such as Buds, contraceptives or condoms) must be used during the study period and within 6 months after the study ends; the serum pregnancy test is negative within 7 days before the study enrollment. , and must be non-lactation subjects; male subjects should agree to adopt contraceptive measures within 6 months after the end of the study period.

Exclusion criteria

Exclusion Criteria:

  • It is known to suffer from spinal cord compression, cancerous meningitis, symptoms with or symptoms control for less than 4 weeks.
  • Combined diseases and medical history:

    1. Have appeared within 3 years or have also suffered from other malignant tumors;
    2. Adverse reactions from previous treatments have not been restored to 5.0 grade≤1;
    3. It affects oral and drug absorption
    4. Those who have received major surgical treatment within 4 weeks before the first medication, obvious traumatic injury or expected to undergo major surgery during the study treatment, or have long-term uncured wounds or fractures;
    5. Congenital bleeding , coagulation dysfunction disease;
    6. Arterial/deep thrombosis events occurred;
    7. Blood pressure control was not ideal;
    8. Major cardiovascular disease;
    9. Uncontrolled ≥CTCAE level 2 within 14 days before the start of study treatment
    10. A history of active tuberculosis, pulmonary fibrosis or pneumonia;
    11. a past or currently associated with interstitial lung disease/pneumonia;
    12. active viral hepatitis and poor control;
    13. treatment is required
    14. uncontrollable kidney disease;
    15. a history of immunodeficiency;
    16. a person who is prepared to undergo or has undergone genealogical bone marrow transplants or solid organ transplants;
    17. uncontrollable diabetes;
    18. a person who suffers from People with epilepsy and need treatment;
    19. People with a history of psychotropic substance abuse and cannot be abstained or have mental disorders.
  • Tumor-related symptoms and treatment:

    1. If it is not controlled, the third gap effusion still needs to be repeatedly drained;
    2. There is lung cancer pharyngitis;
    3. During the study period, the tumor is very likely to invade important blood vessels and cause it Fatal severe bleeding;
    4. Use strong inhibitor or strong inducer, and the drug half-life is less than 3 before the start of the study treatment;
    5. Have received anti-tumor treatment within 3 weeks before the start of the study treatment, and the washing is calculated from the end of the last treatment
    6. Within 2 weeks before the start of the study treatment, Chinese patent medicine treatment with anti-tumor indications was received in the National Medical Products Administration (NMPA) approved drug instructions.
  • Research and treatment related:

    1. Used phosphatidylinositol 3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibitors;
    2. Used fulvestrant or other selective estrogen receptor degrading agents (SERD);
    3. Used in any study drug or drug Allergic to any ingredient or ;
    4. a history of within 28 days before the first medication or planned to undergo live attenuated vaccination during the study period;
    5. is receiving systemic therapy or any other form of therapy, and Continued use within 2 weeks before the start of the study treatment
  • According to the judgment of the researcher, there are situations that seriously endanger the safety of the subject or affect the subject's completion of the research.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules

    TQB3912 tablets 120 mg quaque die (QD), + fulvestrant injection 500 mg quaque 4 week(Q4W) (C1D15),28 days as a treatment cycle. Or TQB3912 tablets 120 mg quaque die(QD)+TQB3616 capsules 80 mg/120 mg QD +fulvestrant injection 500 mg quaque 4 week(Q4W) (C1D15), 28 days as a treatment cycle.

    Drug: TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules

Interventions

  • DrugTQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules

    Protein kinase B(AKT) inhibitors+Cyclin-dependent kinase 4/6(CDK4/6) Inhibitor+Estrogen receptor antagonists.

This study also gives Fulvestrant. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    Phase Ib of Queue 2maximum tolerated dose (MTD, if any)

    Time frame: 4 months after Queue 2 begins enrollment

  2. phase II recommended dose (RP2D)

    Phase II Queue 2: phase II recommended dose (RP2D).

    Time frame: 4 months after Queue 2 begins enrollment

  3. Objective Remission Rate (ORR)

    Cohort 1, Phase II of Cohort 2: Objective Remission Rate (ORR).

    Time frame: 8 to 16 weeks after enrollment

Secondary outcomes

  1. Progression-free survival (PFS)

    Refers to the time from the beginning of the first treatment to the first progression of the disease or death for any cause (whichever occurs first).

    Time frame: From enrollment to disease progression, an average of 14 months

  2. Duration of response (DOR)

    Patient from the date of first documentation of objective remission of the tumor to the date of first documentation of objective progression of the tumor or the date of death due to any cause.

    Time frame: From enrollment to disease progression, an average of 14 months

  3. Disease control rate (DCR)

    Proportion of participants with complete response, partial response, and stable disease as rated by RECIST v1.1 criteria for best overall efficacy after enrollment of all patients.

    Time frame: 8 to 16 weeks after enrollment

  4. Clinical benefit ratio (CBR)

    Refers to the percentage of subjects with complete remission (CR), partial remission (PR), or stable disease (SD) determined by the investigator based on RECIST 1.1 for 24 weeks.

    Time frame: ≥24 weeks after enrollment

  5. Overall survival (OS)

    The time from randomization to death due to any cause.

    Time frame: From enrollment to subject death, it is expected to be evaluated until 5 years

  6. Number of patients with adverse events (AEs) and serious adverse events (SAEs)

    Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: Within 28 days after dosing

  7. Peak time (Tmax)

    Refers to the time after a single dose, the blood drug concentration reaches its peak.

    Time frame: Within 24 hours after dosing

  8. Peak concentration (Cmax)

    Maximum plasma drug concentration.

    Time frame: 30 minuets pre-dose at cycle 1 day 1, 8 and day 28. 30 minuets,1, 2, 3, 4, 6, 8, 12, 24 hours after dose at cycle 1 day 1 and day 28. Each cycle is 28 days

  9. Elimination half life (t1/2)

    The time it takes for the drug to eliminate half of the body, or the time it takes for the blood drug concentration to be reduced by half.

    Time frame: Within 1~7 days after dose

  10. Area under plasma concentration-time curve (AUC0-∞)

    The first dosing begins to extrapolate to an infinity plasma concentration-area under the time curve.

    Time frame: Within 28 days after dosing

07

Study locations

17 sites
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, Anhui 233000, China
  • Fuzhou First General Hospital
    Fuzhou, Fujian 350009, China
  • Quanzhou First Hospital
    Quanzhou, Fujian 362000, China
  • Meizhou peoples Hospital
    Meizhou, Guangdong 514000, China
  • Guizhou Medical University Affiliated Cancer Hospital Co., Ltd
    Guiyang, Guizhou 550001, China
  • Guizhou Provincial People's Hospital
    Guiyang, Guizhou 550002, China
  • Harbin Medical University Cancer
    Harbin, Heilongjiang 150000, China
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430071, China
  • Yongzhou Central Hospital
    Yongzhou, Hunan 425002, China
  • Liaoning Cancer Hospital
    Shenyang, Liaoning 110000, China
  • The First Affiliated Hospital of Xi'an Jiao Tong University
    Xi'an, Shaanxi 710061, China
  • Shanxi Cancer Hospital
    Taiyuan, Shanxi 030000, China
  • Tianjin Cancer Hospital Airport Hospital
    Tianjin, Tianjin Municipality 300202, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin Municipality 300202, China
  • Xinjiang Medical University Affiliated Cancer Hospital
    Ürümqi, Xinjiang 830000, China
  • Ningbo Medical Center Lihuili Hospital
    Ningbo, Zhejiang 315000, China
  • Taizhou Central Hospital (Taizhou University Affiliated Hospital)
    Taizhou, Zhejiang 31800, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Nov 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2025
First posted
Feb 28, 2025
StartActual
May 16, 2025
Primary completionActual
Nov 20, 2025
CompletionActual
Nov 20, 2025
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06851442
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
May 16, 2025
Primary completion
Nov 20, 2025
Completion
Nov 20, 2025
Last update
Dec 12, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion